@article{uneatlantico17868,
          volume = {114},
         journal = {Diagnostic Microbiology and Infectious Disease},
           title = {Efficacy of liposomal amphotericin B for treating post-kala-azar dermal leishmaniasis (PKDL): A systematic review and single-arm meta-analysis},
           month = {Febrero},
          number = {2},
          author = {Deivyd Vieira Silva Cavalcante and Lilia Maria Lima de Oliveira and Noor Husain and Beatriz Ximenes Mendes and Ana Clara Felix de Farias Santos and Luciana Borrigueiro and Lyria de Oliveira Rosa and Christian Ndikuryayo and Sarah Soares Amorim and Lalit Mohan and Fabiana Castro Porto Silva Lopes},
           pages = {117160},
            year = {2026},
             url = {http://repositorio.uneatlantico.es/id/eprint/17868/},
        abstract = {Background
Post-kala-azar dermal leishmaniasis (PKDL) is a skin condition that can become a complication in about 15 \% of patients who have had kala-azar. Despite its significance, treatment options for PKDL are still limited. This systematic review and meta-analysis aim to evaluate the efficacy of amphotericin B for this condition.
Methods
PubMed, Embase, Cochrane, and Web of Science databases were searched for randomized controlled trials (RCTs) that reported the efficacy of Liposomal Amphotericin B in the treatment of PKDL. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Events per 100 observations with 95 \% confidence intervals were performed for outcomes.
Results
Nine studies with 639 patients were included, the treatment durations ranging from 7 to 60 days. The mean age ranged from 9.2 to 31.0 years, and 359 patients were male. The PKDL treatment with liposomal amphotericin B resulted in a cure rate of 91.36 \% (95 \% CI: 76.60-97.15). However, a relapse was observed in 11.42 \% (95 \% CI: 6.20-20.8) of patients. Adverse events were common, with hepatic enzyme elevation (ALT/AST) being the most frequent (61.75 \%; 95 \% CI: 21.81?90.33), followed by fever in 29.93 \% of cases (95 \% CI: 5.09?77.30). Among the more serious side effects, decreased serum potassium was observed in 19.27 \% (95 \% CI: 3.84?58.82), and increased serum creatinine, indicative of nephrotoxicity, occurred in 15.08 \% (95 \% CI: 3.97?43.27). Nausea or vomiting, although less severe, affected 12.36 \% of patients (95 \% CI: 4.81?28.25).
Conclusions
These findings highlight that while liposomal amphotericin B is a potent therapeutic option for PKDL, its administration requires careful management and clinical vigilance to optimize outcomes and minimize risks.}
}